Afatinib-related nonhematologic adverse events: is common evaluation enough for now?

@article{Marinis2014AfatinibrelatedNA,
  title={Afatinib-related nonhematologic adverse events: is common evaluation enough for now?},
  author={Filippo de Marinis and Antonio Passaro},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 8},
  pages={
          864-5
        }
}
(C); Lecia V. Sequist, Boehringer Ingelheim (U), Clovis Oncology (U), Merrimack Pharmaceuticals (U), AstraZeneca (U), GlaxoSmithKline (C) Stock Ownership: None Honoraria: James Chih-Hsin Yang, AstraZeneca, Bayer AG, Roche, Boehringer Ingelheim Research Funding: James Chih-Hsin Yang, Boehringer Ingelheim; Lecia V. Sequist, Boehringer Ingelheim Expert Testimony: None Patents, Royalties, and Licenses: None Other Remuneration: None REFERENCE 1. Haspinger ER, Garassino MC, Torri V, et al: Do we… CONTINUE READING
3
Twitter Mentions